

Growth factor and co-receptor release by structural regulation of substrate metalloprotease accessibility.

Liseth M Parra^{1,2*}, Monika Hartmann^{1*}, Salome Schubach¹, Junzhi Ma¹, Peter Herrlich^{1} and Andreas Herrlich^{2**}**

¹ Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany

² Washington University School of Medicine, Renal Division, St. Louis, MO, USA

* shared first authorship, ** shared senior authorship

To whom correspondence should be addressed: Andreas Herrlich, Associate Professor of Medicine, Washington University School of Medicine in St. Louis, MO email: aherrlich@wustl.edu

Supplemental Figure Legends:

Supplemental Fig. 1: TPA induced cleavage of endogenous CD44 in the human breast cancer cell line MDA-MB-231. Cleavage is inhibited by batimastat, by the PKC inhibitors BIM1 and Gö6976, by okadaic acid and by an active mutant of merlin (see also^{28,29}).

Supplemental Fig. 2: TPA induced increased chymotrypsin sensitivity of endogenous NRG1.

Supplemental Fig. 3: (A) NRG1-S286A reduces protease accessibility of the NRG1 ectodomain to chymotrypsin.

(B) PKC δ knockdown reduces protease accessibility of the NRG1 ectodomain to chymotrypsin.

+ DAPT

DMSO

batimastat

BIM1

Gö6976

okadaic acid

NF2 S518A

kDa

- +

- +

- +

- +


- +

- +

TPA

WB: hCD44
N-term


100—
70—
55—
35—
25—
15—



← CD44fl

WB: hCD44
C-term


35—
15—





← CD44ΔE


WB: GAPDH

40—





A



B

